Johnson Controls International (JCI) Bank of America Industrials, Transportation, & Airlines Key Leaders Conference 2025 summary
Event summary combining transcript, slides, and related documents.
Bank of America Industrials, Transportation, & Airlines Key Leaders Conference 2025 summary
8 Jul, 2026Organizational transformation and resegmentation
Combined field-based and product-based operating models to reduce inefficiency and focus on market needs.
Shifted to a more verticalized approach, tailoring solutions for specific customer segments like healthcare and high-end clients.
Transformation aims to drive higher growth and profitability by aligning teams and simplifying operations.
Sales and operations are now more closely aligned, improving early market signals and inventory management.
Organizational changes implemented in April, with optimization expected over the next few quarters.
Financial performance and cash flow
Focused on improving cash conversion by unwinding factoring, simplifying supply chain, and better procurement.
Significant improvements in cash flow conversion over the past 18 months, overcoming structural headwinds.
Further gains depend on inventory management and lean manufacturing, with benefits expected over the next few years.
Moving toward cash EPS reporting once 100% cash conversion is achieved and sustainable.
Strategic review and portfolio management
Comprehensive portfolio review underway, with all assets under evaluation for performance and fit.
Potential outcomes include divestitures or operational improvements for underperforming assets.
Divestiture closing in Q4, with $5B in proceeds earmarked for share repurchases.
M&A focus is on acquiring complementary technologies and expanding in high-growth verticals and regions.
Latest events from Johnson Controls International
- Q3 delivered strong sales, EPS growth, record backlog, and a raised FY26 outlook.JCI
Q3 2026 - Q2 saw 8% sales growth, 45% adjusted EPS growth, and record backlog, prompting raised guidance.JCI
Q2 2026 - Sales, EPS, and backlog hit records, with raised FY26 guidance and strong demand across regions.JCI
Q1 2026 - Record backlog, strong sales and EPS growth, and robust FY26 outlook driven by innovation.JCI
Q4 2025 - Q3 saw 6% organic sales growth, record backlog, and expanded share repurchase authorization.JCI
Q3 2025 - Q4 organic sales up 10%, margin and EPS rose; FY25 outlook strong with restructuring and growth.JCI
Q4 2024 - Q3 delivered growth, margin expansion, record backlog, and major divestitures amid portfolio shift.JCI
Q3 2024 - Q2 2025 saw 7% organic sales growth, margin expansion, and raised FY25 guidance.JCI
Q2 2025 - Q1 2025 saw 10% organic growth, 39% EPS gain, and raised full-year guidance.JCI
Q1 2025